Novel Drug Delivery Systems-Global Market Status and Trend Report 2016-2026

Table of Contents

Chapter 1 Overview of Novel Drug Delivery Systems

• 1.1 Definition of Novel Drug Delivery Systems in This Report
• 1.2 Commercial Types of Novel Drug Delivery Systems
  • 1.2.1 Liposomes
  • 1.2.2 PEGylated Proteins & Polypeptides
  • 1.2.3 Polymer Nanoparticle
  • 1.2.4 Protein–drug Conjugates
  • 1.2.5 Others
• 1.3 Downstream Application of Novel Drug Delivery Systems
  • 1.3.1 Hospitals & Clinic
  • 1.3.2 Cancer Treatment Centers
  • 1.3.3 Others
• 1.4 Development History of Novel Drug Delivery Systems
• 1.5 Market Status and Trend of Novel Drug Delivery Systems 2016-2026
  • 1.5.1 Global Novel Drug Delivery Systems Market Status and Trend 2016-2026
  • 1.5.2 Regional Novel Drug Delivery Systems Market Status and Trend 2016-2026

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Novel Drug Delivery Systems 2016-2021
• 2.2 Production Market of Novel Drug Delivery Systems by Regions
  • 2.2.1 Production Volume of Novel Drug Delivery Systems by Regions
  • 2.2.2 Production Value of Novel Drug Delivery Systems by Regions
• 2.3 Demand Market of Novel Drug Delivery Systems by Regions
• 2.4 Production and Demand Status of Novel Drug Delivery Systems by Regions
  • 2.4.1 Production and Demand Status of Novel Drug Delivery Systems by Regions 2016-2021
  • 2.4.2 Import and Export Status of Novel Drug Delivery Systems by Regions 2016-2021

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Novel Drug Delivery Systems by Types
• 3.2 Production Value of Novel Drug Delivery Systems by Types
• 3.3 Market Forecast of Novel Drug Delivery Systems by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Novel Drug Delivery Systems by Downstream Industry
• 4.2 Market Forecast of Novel Drug Delivery Systems by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Novel Drug Delivery Systems

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Novel Drug Delivery Systems Downstream Industry Situation and Trend Overview

Chapter 6 Novel Drug Delivery Systems Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Novel Drug Delivery Systems by Major Manufacturers
• 6.2 Production Value of Novel Drug Delivery Systems by Major Manufacturers
• 6.3 Basic Information of Novel Drug Delivery Systems by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Novel Drug Delivery Systems Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Novel Drug Delivery Systems Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Novel Drug Delivery Systems Major Manufacturers Introduction and Market Data

• 7.1 Amgen
  • 7.1.1 Company profile
  • 7.1.2 Representative Novel Drug Delivery Systems Product
  • 7.1.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Amgen
• 7.2 Teva
  • 7.2.1 Company profile
  • 7.2.2 Representative Novel Drug Delivery Systems Product
  • 7.2.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Teva
• 7.3 Roche
  • 7.3.1 Company profile
  • 7.3.2 Representative Novel Drug Delivery Systems Product
  • 7.3.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Roche
• 7.4 UCB (Union Chimique Belge)
  • 7.4.1 Company profile
  • 7.4.2 Representative Novel Drug Delivery Systems Product
  • 7.4.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of UCB (Union Chimique Belge)
• 7.5 Celgene
  • 7.5.1 Company profile
  • 7.5.2 Representative Novel Drug Delivery Systems Product
  • 7.5.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Celgene
• 7.6 Merck
  • 7.6.1 Company profile
  • 7.6.2 Representative Novel Drug Delivery Systems Product
  • 7.6.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Merck
• 7.7 Gilead Sciences
  • 7.7.1 Company profile
  • 7.7.2 Representative Novel Drug Delivery Systems Product
  • 7.7.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Gilead Sciences
• 7.8 Sanofi
  • 7.8.1 Company profile
  • 7.8.2 Representative Novel Drug Delivery Systems Product
  • 7.8.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Sanofi
• 7.9 Pfizer
  • 7.9.1 Company profile
  • 7.9.2 Representative Novel Drug Delivery Systems Product
  • 7.9.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Pfizer
• 7.10 Takeda
  • 7.10.1 Company profile
  • 7.10.2 Representative Novel Drug Delivery Systems Product
  • 7.10.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Takeda
• 7.11 Bausch&Lomb
  • 7.11.1 Company profile
  • 7.11.2 Representative Novel Drug Delivery Systems Product
  • 7.11.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Bausch&Lomb
• 7.12 Samyang Biopharmaceuticals
  • 7.12.1 Company profile
  • 7.12.2 Representative Novel Drug Delivery Systems Product
  • 7.12.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Samyang Biopharmaceuticals
• 7.13 Johnson & Johnson
  • 7.13.1 Company profile
  • 7.13.2 Representative Novel Drug Delivery Systems Product
  • 7.13.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Johnson & Johnson
• 7.14 TOLMAR
  • 7.14.1 Company profile
  • 7.14.2 Representative Novel Drug Delivery Systems Product
  • 7.14.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of TOLMAR
• 7.15 Astellas
  • 7.15.1 Company profile
  • 7.15.2 Representative Novel Drug Delivery Systems Product
  • 7.15.3 Novel Drug Delivery Systems Sales, Revenue, Price and Gross Margin of Astellas
• 7.16 AMAG Pharmaceuticals
• 7.17 AbbVie
• 7.18 Dr Reddy
• 7.19 AstraZeneca
• 7.20 Aspen
• 7.21 Acrotech Biopharma
• 7.22 TWi Pharmaceuticals

Chapter 8 Upstream and Downstream Market Analysis of Novel Drug Delivery Systems

• 8.1 Industry Chain of Novel Drug Delivery Systems
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Novel Drug Delivery Systems

• 9.1 Cost Structure Analysis of Novel Drug Delivery Systems
• 9.2 Raw Materials Cost Analysis of Novel Drug Delivery Systems
• 9.3 Labor Cost Analysis of Novel Drug Delivery Systems
• 9.4 Manufacturing Expenses Analysis of Novel Drug Delivery Systems

Chapter 10 Marketing Status Analysis of Novel Drug Delivery Systems

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources